CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial

Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial.

According to Center Laboratories, the orally administered small molecule drug candidate delivered significant reductions in glycated hemoglobin (HbA1c) in comparison to the placebo group.

The phase 2 clinical trial is a proof of concept (PoC) study being held as per the US FDA’s guidance to primarily evaluate its glycemic controlling effect. CenterLab also included Homeostasis model2 assessment β-cell (HOMA2-β) as a secondary endpoint to show CS02’s capability in beta cell preservation.

The Taiwanese pharma company said that the CS02 phase 2 clinical trials showed that the small molecule decreased HbA1c by a significant extent, besides showing top performance in the preservation of the pancreatic beta cell function with HOMA2-β increased by 13.45%.

Robert Hsu – the GM of CenterLab said: “CenterLab is highly committed to patients’ unmet needs, thus, CenterLab aims to bring on better treatments which is more cost-effective and safer compared to other treatments. We believe CS02, as a potential blockbuster for diabetes treatment, has a role in improving patients’ life quality.”

Related posts

• Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia (0)
• ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options (0)
• Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial (0)
• Masimo gets FDA clearance for Centroid patient monitoring sensor (0)
• Zogenix bags Fintepla FDA approval for Dravet syndrome treatment (0)
• Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies (0)
• Roche gets FDA nod for cobas EZH2 Mutation Test as companion diagnostic for follicular lymphoma patients (0)
• Mylan gets favorable court decision in Biogen’s Tecfidera patent case (0)
• Ultragenyx Pharmaceutical, Kyowa Kirin bag Crysvita FDA approval for TIO (0)
• Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD (0)